Together with the fact that MET404 is commonly overexpressed in GBM and highly correlated with the p-MET status, our results suggested that MET404 is an ideal target in MET-hyperactivated GBM, especially when used in combination with other MET inhibitors (Fig. 7h). Here, MET is linked to glioblastoma.